The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note | Alive

About Gigamune

GigaMune is a cancer cell therapy company focused on T cell receptor discovery and development. Its patented TCR technologies facilitate the discovery of rare TCRs from the immune repertoires of patients with response to cancer.

Gigamune Headquarter Location

One Tower Place, Suite 750

South San Francisco, California, 9408,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Gigamune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gigamune is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Gigamune Patents

Gigamune has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics



Immunology, Immune system, Transcription factors, Olfactory receptors, Biotechnology


Application Date


Grant Date


Related Topics

Immunology, Immune system, Transcription factors, Olfactory receptors, Biotechnology



Latest Gigamune News

Champions Oncology, GigaMune collaborate on next-gen T cell therapies

Feb 15, 2022

Champions Oncology ( CSBR +2.2%) is collaborating with GigaMune for next generation T cell therapies and cancer diagnostics. The partnership will combine Champions' novel autologous Tumor Infiltrating Lymphocyte (TIL) platform with GigaMune's T Cell Receptor (TCR) Discovery platform to accelerate the development of next generation T cell therapies and cancer diagnostics, through the identification of novel TCR sequences. The planned partnership will use GigaMune's proprietary TCR discovery and validation workflow to create a library of natively paired TCR sequences derived from Champions' Autologous TIL platform. Under the agreement, Champions will have the right to select a specified number of TCRs from the library for further, wholly owned, development. The remaining libraries will be jointly owned by Champions and GigaMune for commercialization, with commercial efforts led by Champions. "With these TCR libraries co-developed with GigaMune, we plan to explore the possible development of novel cell therapies, expand upon our early detection efforts, and commercialize the bulk of the TCR libraries through partnerships and our Lumin platform," said Champions President and CEO Ronnie Morris. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

  • When was Gigamune founded?

    Gigamune was founded in 2017.

  • Where is Gigamune's headquarters?

    Gigamune's headquarters is located at One Tower Place, Suite 750, South San Francisco.

  • What is Gigamune's latest funding round?

    Gigamune's latest funding round is Convertible Note.

  • Who are the investors of Gigamune?

    Investors of Gigamune include GigaGen.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.